Search: onr:"swepub:oai:prod.swepub.kib.ki.se:137567904" >
Menopausal hormone ...
Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway
- Article/chapterEnglish2017
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:137567904
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:137567904URI
-
https://doi.org/10.1136/bmjopen-2017-017639DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
With the present study, we aimed to investigate the association between menopausal hormone therapy (HT) and risk of colorectal cancer (CRC).SettingCohort study based on the linkage of Norwegian population-based registries.ParticipantsWe selected 466822 Norwegian women, aged 55–79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user.Outcome measuresThe outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence.ResultsDuring the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen–progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively.ConclusionsIn our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Stoer, NC
(author)
-
Sakshaug, S
(author)
-
Graff-Iversen, S
(author)
-
Vangen, S
(author)
-
Hofvind, S
(author)
-
de Lange, T
(author)
-
Bagnardi, V
(author)
-
Ursin, G
(author)
-
Weiderpass, EKarolinska Institutet
(author)
-
Karolinska Institutet
(creator_code:org_t)
Related titles
-
In:BMJ open: BMJ7:11, s. e017639-2044-6055
Internet link
Find in a library
-
BMJ open
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Botteri, E
-
Stoer, NC
-
Sakshaug, S
-
Graff-Iversen, S
-
Vangen, S
-
Hofvind, S
-
show more...
-
de Lange, T
-
Bagnardi, V
-
Ursin, G
-
Weiderpass, E
-
show less...
- Articles in the publication
-
BMJ open
- By the university
-
Karolinska Institutet